Failure to maintain endoscopic remission · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with active Crohn's disease
Antibiotic showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
Antibiotic showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Antibiotic showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Failure to induce clinical remission at end of study · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to maintain remission · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to maintain remission · people with moderate to severe Crohn's disease in remission
Ustekinumab showed no clear difference in failure to maintain clinical remission compared with placebo (moderate certainty).
2 findings from 1 review
Adverse events · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Failure to maintain clinical response · people with moderate to severe Crohn's disease in remission
Ustekinumab probably leads to lower failure to maintain clinical response compared with placebo (moderate certainty).
2 findings from 1 review
Adverse events · people with moderate to severe Crohn's disease in remission
Ustekinumab showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · people with moderate to severe Crohn's disease in remission
Ustekinumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with moderate to severe Crohn's disease in remission
Ustekinumab showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Failure to maintain remission · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in failure to maintain clinical remission compared with placebo (low certainty).
1 finding from 1 review
Failure to maintain clinical response · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in failure to maintain clinical response compared with placebo (low certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Certolizumab pegol probably leads to higher clinical remission compared with placebo (moderate certainty).
1 finding from 1 review
Clinical response · Patients with active Crohn's disease
Certolizumab pegol probably leads to higher clinical response compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
Certolizumab pegol showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Failure to induce remission at 10 weeks · Patients with active Crohn's disease
One infusion of natalizumab (300 mg or 3 mg/kg) probably leads to lower failure to induce remission at 2 weeks compared with placebo (moderate certainty).
1 finding from 1 review